Febuxostat
M04AA
Præparater
| Indholdsstof | Navn og firma | Dispform og styrke | Pakning | Pris enh. | Pris DDD |
|---|---|---|---|---|---|
| Febuxostat | Adenuric PharmaPrim
|
filmovertrukne tabletter 80 mg | 28 stk. (blister) | 9,57 | 9,57 |
| Febuxostat | Adenuric PharmaPrim
|
filmovertrukne tabletter 80 mg | 84 stk. (blister) | 9,05 | 9,05 |
| Febuxostat | Adenuric PharmaPrim
|
filmovertrukne tabletter 120 mg | 28 stk. (blister) | 9,47 | 6,32 |
| Febuxostat | Febuxostat "Krka" KRKA
|
filmovertrukne tabletter 80 mg | 28 stk. (blister) | 14,65 | 14,65 |
| Febuxostat | Febuxostat "Medical Valley" Medical Valley
Udgået
27.10.2025
|
filmovertrukne tabletter 80 mg | 28 stk. (blister) | ||
| Febuxostat | Febuxostat "Teva" TEVA
|
filmovertrukne tabletter 80 mg | 28 stk. (blister) | 9,57 | 9,57 |
| Febuxostat | Febuxostat "Teva" TEVA
|
filmovertrukne tabletter 120 mg | 28 stk. (blister) | 9,43 | 6,29 |
Referencer
5342. Mackenzie IS, Ford I, Nuki G et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396:1745-57, https://pubmed.ncbi.nlm.nih.gov/33181081/ (Lokaliseret 23. oktober 2023)
5341. White WB, Saag KG, Becker MA et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018; 378:1200-10, https://pubmed.ncbi.nlm.nih.gov/29527974/ (Lokaliseret 23. oktober 2023)
2001. Becker MA, Schumacher HR, Wortmann RL et al. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. The New England Journal of Medicine. 2005; 353:2450-61, https://pubmed.ncbi.nlm.nih.gov/16339094/ (Lokaliseret 26. april 2023)
